SEBIVO(R) (Telbivudine) Approved In China As New Treatment Option For Patients With Chronic Hepatitis B
Sat, 03 Mar 2007 08:00 AM EST
... Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that SEBIVO(R) (telbivudine) has received approval from the Chinese State Food and Drug Administration (SFDA) as a once-a-day treatment, taken orally with or without food, for the treatment of chronic hepatitis B (CHB). [click link for full article] ...
Related Topics
- Hepatitis C
- Hepatitis B
- Hepatitis A
- Hepatitis
- Autoimmune Hepatitis
- Chronic Pain
- Pain - Chronic
- Chronic Fatigue Syndrome
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Hepatitis B Vaccine
- Chronic Diseases
- Chronic Hepatitis C: Current Disease Management
- Leukemia, Chronic Lymphocytic
- Chronic Lymphocytic Leukemia
- Fatigue
- Chronic Obstructive Pulmonary Disease
- Pancreatitis
- Pain Control
- What Your Female Patients Want to Know About Bladder Control

Not Signed In -


